648 related articles for article (PubMed ID: 19651171)
1. A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age.
Langley JM; Sales V; McGeer A; Guasparini R; Predy G; Meekison W; Li M; Capellan J; Wang E
Vaccine; 2009 Sep; 27(42):5913-9. PubMed ID: 19651171
[TBL] [Abstract][Full Text] [Related]
2. Murine host responses to respiratory syncytial virus (RSV) following intranasal administration of a Protollin-adjuvanted, epitope-enhanced recombinant G protein vaccine.
Huang Y; Cyr SL; Burt DS; Anderson R
J Clin Virol; 2009 Apr; 44(4):287-91. PubMed ID: 19233722
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.
Roman F; Vaman T; Gerlach B; Markendorf A; Gillard P; Devaster JM
Vaccine; 2010 Feb; 28(7):1740-5. PubMed ID: 20034605
[TBL] [Abstract][Full Text] [Related]
4. Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation.
Stegmann T; Kamphuis T; Meijerhof T; Goud E; de Haan A; Wilschut J
Vaccine; 2010 Aug; 28(34):5543-50. PubMed ID: 20600502
[TBL] [Abstract][Full Text] [Related]
5. Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques.
Elliott MB; Chen T; Terio NB; Chong SY; Abdullah R; Luckay A; Egan MA; Boutilier LA; Melville K; Lerch RA; Long D; Eldridge JH; Parks CL; Udem SA; Hancock GE
Vaccine; 2007 Oct; 25(41):7132-44. PubMed ID: 17850933
[TBL] [Abstract][Full Text] [Related]
6. Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology.
Cyr SL; Jones T; Stoica-Popescu I; Brewer A; Chabot S; Lussier M; Burt D; Ward BJ
Vaccine; 2007 Jul; 25(29):5378-89. PubMed ID: 17561317
[TBL] [Abstract][Full Text] [Related]
7. A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models.
Lambert SL; Aslam S; Stillman E; MacPhail M; Nelson C; Ro B; Sweetwood R; Lei YM; Woo JC; Tang RS
PLoS One; 2015; 10(3):e0119509. PubMed ID: 25793508
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults.
Power UF; Nguyen TN; Rietveld E; de Swart RL; Groen J; Osterhaus AD; de Groot R; Corvaia N; Beck A; Bouveret-Le-Cam N; Bonnefoy JY
J Infect Dis; 2001 Dec; 184(11):1456-60. PubMed ID: 11709789
[TBL] [Abstract][Full Text] [Related]
9. A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age.
August A; Glenn GM; Kpamegan E; Hickman SP; Jani D; Lu H; Thomas DN; Wen J; Piedra PA; Fries LF
Vaccine; 2017 Jun; 35(30):3749-3759. PubMed ID: 28579233
[TBL] [Abstract][Full Text] [Related]
10. A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant.
Langley JM; Aggarwal N; Toma A; Halperin SA; McNeil SA; Fissette L; Dewé W; Leyssen M; Toussaint JF; Dieussaert I
J Infect Dis; 2017 Jan; 215(1):24-33. PubMed ID: 27694633
[TBL] [Abstract][Full Text] [Related]
11. A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age.
Glenn GM; Fries LF; Thomas DN; Smith G; Kpamegan E; Lu H; Flyer D; Jani D; Hickman SP; Piedra PA
J Infect Dis; 2016 Feb; 213(3):411-22. PubMed ID: 26259809
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines--nonadjuvanted vaccine or vaccine adjuvanted with alum--given concomitantly with influenza vaccine to high-risk elderly individuals.
Falsey AR; Walsh EE; Capellan J; Gravenstein S; Zambon M; Yau E; Gorse GJ; Edelman R; Hayden FG; McElhaney JE; Neuzil KM; Nichol KL; Simões EA; Wright PF; Sales VM
J Infect Dis; 2008 Nov; 198(9):1317-26. PubMed ID: 18855558
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use.
Hehme N; Engelmann H; Kuenzel W; Neumeier E; Saenger R
Virus Res; 2004 Jul; 103(1-2):163-71. PubMed ID: 15163505
[TBL] [Abstract][Full Text] [Related]
14. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
[TBL] [Abstract][Full Text] [Related]
15. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses.
Ansaldi F; Bacilieri S; Durando P; Sticchi L; Valle L; Montomoli E; Icardi G; Gasparini R; Crovari P
Vaccine; 2008 Mar; 26(12):1525-9. PubMed ID: 18294741
[TBL] [Abstract][Full Text] [Related]
16. Respiratory syncytial virus subunit vaccine based on a recombinant fusion protein expressed transiently in mammalian cells.
Nallet S; Amacker M; Westerfeld N; Baldi L; König I; Hacker DL; Zaborosch C; Zurbriggen R; Wurm FM
Vaccine; 2009 Oct; 27(46):6415-9. PubMed ID: 19559121
[TBL] [Abstract][Full Text] [Related]
17. An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults.
Falloon J; Yu J; Esser MT; Villafana T; Yu L; Dubovsky F; Takas T; Levin MJ; Falsey AR
J Infect Dis; 2017 Dec; 216(11):1362-1370. PubMed ID: 29029260
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.
Nolan T; Richmond PC; Formica NT; Höschler K; Skeljo MV; Stoney T; McVernon J; Hartel G; Sawlwin DC; Bennet J; Ryan D; Basser RL; Zambon MC
Vaccine; 2008 Nov; 26(50):6383-91. PubMed ID: 18801398
[TBL] [Abstract][Full Text] [Related]
20. Immunopathology of RSV infection: prospects for developing vaccines without this complication.
van Drunen Littel-van den Hurk S; Mapletoft JW; Arsic N; Kovacs-Nolan J
Rev Med Virol; 2007; 17(1):5-34. PubMed ID: 17004293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]